Fampridine immediate-release

Drug Profile

Fampridine immediate-release

Alternative Names: 4-Aminopyridine immediate release; 4-AP - Neurorecovery; 4-AP IR; Ampydin IR; Fampridine IR

Latest Information Update: 12 Feb 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neurorecovery
  • Class Aminopyridines; Small molecules
  • Mechanism of Action Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Guillain-Barre syndrome

Highest Development Phases

  • Suspended Guillain-Barre syndrome

Most Recent Events

  • 22 Sep 2014 Biomarkers information updated
  • 12 Feb 2008 Suspended - Phase-II for Guillain-Barre syndrome in USA (PO)
  • 05 Feb 2008 Acorda Therapeutics acquires ownership of Neurorecovery's fampridine immediate-release product
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top